Alzamend Neuro Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28

Reuters
09/11
<a href="https://laohu8.com/S/ALZN">Alzamend Neuro</a> Inc. Reports No Revenue for Quarter Ending July 31, 2025; Net Loss Per Share at $1.28

Alzamend Neuro Inc. released its quarterly financial results for the period ending July 31, 2025. The company did not report any revenue for this quarter, consistent with the same period in 2024, as its product candidates AL001 and ALZN002 are still in the clinical stage of development. The net loss per common share was reported at $1.28, based on a basic and diluted weighted average of 2.1 million common shares outstanding. This is a decrease compared to a net loss per common share of $11.42 in the previous period, which was based on a lower average of 85,314 common shares outstanding. The company does not anticipate generating revenue in the foreseeable future as its product candidates require extensive development, regulatory approval, and significant investment before they can be marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-25-013609), on September 10, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10